C4 Therapeutics, Inc.
Heterocyclic degronimers for target protein degradation

Last updated:

Abstract:

This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) ("Degrons"), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.

Status:
Grant
Type:

Utility

Filling date:

11 May 2020

Issue date:

2 Feb 2021